Go to the scene: TH9 cells superior migration ability to the lungs explains their exceptional anticancer efficacy

dc.contributor.authorXu, Jiazhi
dc.contributor.authorApetoh, Lionel
dc.contributor.departmentMicrobiology and Immunology, School of Medicine
dc.date.accessioned2025-05-14T10:39:02Z
dc.date.available2025-05-14T10:39:02Z
dc.date.issued2025-04-28
dc.description.abstractAntibodies against immune checkpoints are now routinely administered as a first line of treatment against metastatic lung cancer. Resistance to immune checkpoint inhibitors is, however, frequent, underscoring the need to find alternative treatments. Adoptive T-cell therapy has recently proven effective in treating patient's refractory to immune checkpoint inhibitors. This provides impetus to characterize the T-cell subsets best able to tackle tumors. The anticancer activities of IL-9-producing CD4 T helper cells (TH9 cells) were identified in melanoma in 2012. TH9 cells feature strong antimelanoma effects thanks to their production of interleukin (IL)-9 and the activation of innate and adaptive immune effectors. The ability of TH9 cells to prevent the growth of triple-negative breast cancer (TNBC) and osteosarcoma (OS), which commonly metastasize to the lungs, is elusive. In this commentary, we discuss the findings of Chen et al reported in the JITC demonstrating that TH9 cells are lung-tropic and eliminate TNBC and OS cells developing in the lungs. We also highlight how these investigations are in line with recent studies indicating that the adoptive transfer of IL-9-producing T cells eliminate aggressive cancers, including hematological tumors like leukemia and solid tumors such as glioblastoma. Altogether, these findings over the past 13 years support the clinical evaluation of TH9 cells in the adoptive therapy of cancer.
dc.eprint.versionFinal published version
dc.identifier.citationXu J, Apetoh L. Go to the scene: TH9 cells superior migration ability to the lungs explains their exceptional anticancer efficacy. J Immunother Cancer. 2025;13(4):e011522. Published 2025 Apr 28. doi:10.1136/jitc-2025-011522
dc.identifier.urihttps://hdl.handle.net/1805/48092
dc.language.isoen_US
dc.publisherBMJ
dc.relation.isversionof10.1136/jitc-2025-011522
dc.relation.journalJournal for Immunotherapy of Cancer
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourcePMC
dc.subjectAdoptive cell therapy
dc.subjectImmune checkpoint inhibitor
dc.subjectT cell
dc.titleGo to the scene: TH9 cells superior migration ability to the lungs explains their exceptional anticancer efficacy
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Xu2025Go-CCBYNC.pdf
Size:
836.66 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: